--- title: "今日下午開放預約，北京市開展互聯網診療首診試點" description: "北京市於 1 月 31 日啓動互聯網診療首診服務試點，首批在北京兒童醫院和首都兒童醫學中心的 3 個兒科亞專業開展。該服務為首診患者提供線上預問診、線上診療及藥品配送等功能，旨在保證診療安全和質量，醫生可通過互聯網完成首次診斷並開具處方。" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/274374913.md" published_at: "2026-01-31T04:07:20.000Z" --- # 今日下午開放預約，北京市開展互聯網診療首診試點 > 北京市於 1 月 31 日啓動互聯網診療首診服務試點，首批在北京兒童醫院和首都兒童醫學中心的 3 個兒科亞專業開展。該服務為首診患者提供線上預問診、線上診療及藥品配送等功能，旨在保證診療安全和質量，醫生可通過互聯網完成首次診斷並開具處方。 1 月 31 日，北京市啓動互聯網診療首診服務試點，首批試點在北京兒童醫院和首都兒童醫學中心的 3 個兒科亞專業開展，可為首診患者提供線上預問診、線上診療、藥品配送等服務。區別於目前已經開展的互聯網複診，此次開展的互聯網診療首診試點工作，是在保證診療安全和質量的前提下，在試點醫療機構的試點診療專業進行的有益嘗試，醫生通過互聯網即可完成首次診斷並開具處方。（北京日報） ### Related Stocks - [512010.CN - 易方達滬深300醫藥ETF](https://longbridge.com/zh-HK/quote/512010.CN.md) - [01099.HK - 國藥控股](https://longbridge.com/zh-HK/quote/01099.HK.md) - [03320.HK - 華潤醫藥](https://longbridge.com/zh-HK/quote/03320.HK.md) - [510660.CN - 華夏醫藥ETF](https://longbridge.com/zh-HK/quote/510660.CN.md) - [562600.CN - 華夏中證全指醫療器械ETF](https://longbridge.com/zh-HK/quote/562600.CN.md) - [601607.CN - 上海醫藥](https://longbridge.com/zh-HK/quote/601607.CN.md) - [159898.CN - 招商中證全指醫療器械ETF](https://longbridge.com/zh-HK/quote/159898.CN.md) - [512290.CN - 國泰中證生物醫藥ETF](https://longbridge.com/zh-HK/quote/512290.CN.md) - [00241.HK - 阿里健康](https://longbridge.com/zh-HK/quote/00241.HK.md) - [06618.HK - 京東健康](https://longbridge.com/zh-HK/quote/06618.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Sinopharm Group's Nine-Month Profit Rises Despite Revenue Drop | Sinopharm Group's Nine-Month Profit Rises Despite Revenue Drop | [Link](https://longbridge.com/zh-HK/news/262800706.md) | | Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership | Sinopharm Group's renewed distribution partnership with Shanghai Henlius Biotech extends their collaboration until 2028. | [Link](https://longbridge.com/zh-HK/news/269631888.md) | | Finland's Modulight Q4 revenue rises, helped by growth in PPT business | Finland's Modulight reported a 21% year-over-year increase in Q4 revenue, reaching EUR 1.74 million, with an EBITDA of E | [Link](https://longbridge.com/zh-HK/news/276428080.md) | | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-HK/news/276024005.md) | | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。